Group 1 - The company reported a record revenue of approximately HKD 6,107,320,000 for the six months ending June 30, 2025, representing a year-on-year increase of about 1.0% [1] - Revenue in RMB terms increased by approximately 2.0% year-on-year, and if excluding the impact of the tenth batch of centralized procurement price reductions, the revenue in RMB terms increased by approximately 13.0% [1] - Revenue from innovative and barrier products accounted for about 51.0% of total revenue, an increase of 14.9 percentage points compared to the same period last year [1] Group 2 - The profit attributable to the company's owners for the period was approximately HKD 1,169,020,000, a decrease of about 25.0% compared to the same period in 2024 [2] - Excluding the impact of RMB and HKD exchange rate fluctuations, the profit decreased by approximately 24.2% compared to 2024 [2] - The fair value change and disposal gains from the investment in Telix amounted to approximately HKD 151,730,000, a decrease of HKD 324,910,000 compared to the same period last year [2] Group 3 - The company continued to invest resources in the advancement of research projects and the introduction of innovative projects, with total investment in R&D and related expenditures amounting to approximately HKD 1,022,000,000 [2]
远大医药(00512.HK)中期拥有人应占溢利约11.69亿港元 同比下降约25.0%